The Value of GLI1 and P16 Immunohistochemistry in the Premolecular Screening for GLI1-altered Mesenchymal Neoplasms

Overview

Journal Virchows Arch

Specialties Cell Biology
Molecular Biology
Pathology

Date 2023 Nov 8

PMID 37940743

Authors

Isidro Machado

Abbas Agaimy

Francisco Giner

Samuel Navarro

Michael Michal

Julia Bridge

Reyes Claramunt

Jose Antonio Lopez-Guerrero

Javier Alcacer

Konstantinos Linos

Antonio Llombart-Bosch

Affiliations

Soon will be listed here.

Abstract

Mesenchymal neoplasms with GLI1 alterations have recently been reported in several anatomic locations. Their morphology and immunohistochemistry (IHC) are nonspecific, making their recognition a true challenge. To assess the diagnostic value of GLI1 and p16 IHC for identifying GLI1-altered neoplasms, we evaluated 12 such neoplasms (6 GLI1-amplified and 6 with GLI1-fusions) using the GLI1 IHC. Additionally, we evaluated some of their morphological and molecular mimickers, including glomangiomas, Ewing sarcomas (ES), myxoid liposarcomas, and MDM2/CDK4-amplified sarcomas (well-differentiated liposarcoma/WDLPS, dedifferentiated liposarcoma/DDLPS, and intimal sarcoma). All successfully tested GLI1-altered tumors (11/11) demonstrated at least moderate/strong nuclear and/or cytoplasmic GLI1 IHC positivity. GLI1-amplified tumors exhibited a moderate/strong predominantly nuclear staining, compared to a moderate, patchy, and predominantly cytoplasmic GLI1 positivity in GLI1-fusion tumors. Among their mimics, GLI1 immunoreactivity, either cytoplasmic or nuclear, was observed in intimal sarcoma (3/3) and WDLPS/DDLPS (22/25). GLI1 IHC demonstrated 92% sensitivity and 90.8% specificity in diagnosing GLI1-altered neoplasms. Strong/moderate nuclear/cytoplasmic p16 immunoexpression was noted in all GLI1-amplified tumors compared to none of fused cases. Overall, the GLI1/p16 combination demonstrated a sensitivity and specificity of 100% and 93% for GLI1-amplified tumors. In conclusion, we confirm that GLI1 IHC represents a good, quick, and cheap helpful screening tool. The inclusion of p16 may aid in pre-screening for potential GLI1-amplified neoplasms and provide insights on which tumors warrant further molecular testing.

Citing Articles

-Rearranged Enteric Tumors: Updates on Clinicopathologic and Molecular Genetics Features.

Younes A, Mejbel H Cells. 2025; 14(2).

PMID: 39851545 PMC: 11763425. DOI: 10.3390/cells14020118.

GLI1::FOXO4-rearranged kidney tumors: a potentially distinct renal subtype within the spectrum of GLI1-altered tumors?.

Pancsa T, Klubickova N, Dashti N, Machado I, Llombart-Bosch A, Linos K Virchows Arch. 2024; .

PMID: 39688667 DOI: 10.1007/s00428-024-03998-z.

The Combined Immunohistochemical Expression of GLI1 and BCOR in Synovial Sarcomas for the Identification of Three Risk Groups and Their Prognostic Outcomes: A Study of 52 Patients.

Giner F, Medina-Ceballos E, Lopez-Reig R, Machado I, Lopez-Guerrero J, Navarro S Int J Mol Sci. 2024; 25(14).

PMID: 39062853 PMC: 11276717. DOI: 10.3390/ijms25147615.

Molecularly defined sinonasal malignancies: an overview with focus on the current WHO classification and recently described provisional entities.

Skalova A, Agaimy A, Bradova M, Vander Poorten V, Hanna E, Guntinas-Lichius O Virchows Arch. 2024; 484(6):885-900.

PMID: 38491228 PMC: 11186917. DOI: 10.1007/s00428-024-03775-y.

Soft Tissue Sarcomas with Chromosomal Alterations in the 12q13-15 Region: Differential Diagnosis and Therapeutic Implications.

Lavernia J, Claramunt R, Romero I, Lopez-Guerrero J, Llombart-Bosch A, Machado I Cancers (Basel). 2024; 16(2).

PMID: 38275873 PMC: 10814159. DOI: 10.3390/cancers16020432.

References

Liu Y, Huang J, Sun J, Su M, Yang D, Zhao M . GLI1 amplified/fused mesenchymal tumor: A case report and review of the literature. Oral Oncol. 2022; 129:105897. DOI: 10.1016/j.oraloncology.2022.105897. View

Agaram N, Zhang L, Sung Y, Singer S, Stevens T, Prieto-Granada C . GLI1-amplifications expand the spectrum of soft tissue neoplasms defined by GLI1 gene fusions. Mod Pathol. 2019; 32(11):1617-1626. PMC: 6821565. DOI: 10.1038/s41379-019-0293-x. View

Mosquera J, Sboner A, Zhang L, Chen C, Sung Y, Chen H . Novel MIR143-NOTCH fusions in benign and malignant glomus tumors. Genes Chromosomes Cancer. 2013; 52(11):1075-87. PMC: 3889711. DOI: 10.1002/gcc.22102. View

Rollins B, Cassarino D, Lindberg M . Primary cutaneous epithelioid mesenchymal neoplasm with ACTB-GLI1 fusion: a case report. J Cutan Pathol. 2021; 49(3):284-287. DOI: 10.1111/cup.14152. View

Dahlen A, Fletcher C, Mertens F, Fletcher J, Perez-Atayde A, Hicks M . Activation of the GLI oncogene through fusion with the beta-actin gene (ACTB) in a group of distinctive pericytic neoplasms: pericytoma with t(7;12). Am J Pathol. 2004; 164(5):1645-53. PMC: 1615655. DOI: 10.1016/s0002-9440(10)63723-6. View

Didiasova M, Schaefer L, Wygrecka M . Targeting GLI Transcription Factors in Cancer. Molecules. 2018; 23(5). PMC: 6100584. DOI: 10.3390/molecules23051003. View

Jessurun J, Orr C, McNulty S, Hagen C, Alnajar H, Wilkes D . GLI1 -Rearranged Enteric Tumor : Expanding the Spectrum of Gastrointestinal Neoplasms With GLI1 Gene Fusions. Am J Surg Pathol. 2022; 47(1):65-73. DOI: 10.1097/PAS.0000000000001950. View

Spans L, Fletcher C, Antonescu C, Rouquette A, Coindre J, Sciot R . Recurrent MALAT1-GLI1 oncogenic fusion and GLI1 up-regulation define a subset of plexiform fibromyxoma. J Pathol. 2016; 239(3):335-43. PMC: 5586099. DOI: 10.1002/path.4730. View

Khatib Z, Matsushime H, Valentine M, Shapiro D, Sherr C, Look A . Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res. 1993; 53(22):5535-41. View

10.

Kerr D, Pinto A, Subhawong T, Wilky B, Schlumbrecht M, Antonescu C . Pericytoma With t(7;12) and ACTB-GLI1 Fusion: Reevaluation of an Unusual Entity and its Relationship to the Spectrum of GLI1 Fusion-related Neoplasms. Am J Surg Pathol. 2019; 43(12):1682-1692. PMC: 6851481. DOI: 10.1097/PAS.0000000000001360. View

11.

Xu B, Chang K, Folpe A, Kao Y, Wey S, Huang H . Head and Neck Mesenchymal Neoplasms With GLI1 Gene Alterations: A Pathologic Entity With Distinct Histologic Features and Potential for Distant Metastasis. Am J Surg Pathol. 2020; 44(6):729-737. PMC: 7225037. DOI: 10.1097/PAS.0000000000001439. View

12.

Thway K, Jones R, Noujaim J, Zaidi S, Miah A, Fisher C . Dedifferentiated Liposarcoma: Updates on Morphology, Genetics, and Therapeutic Strategies. Adv Anat Pathol. 2015; 23(1):30-40. DOI: 10.1097/PAP.0000000000000101. View

13.

Papke Jr D, Dickson B, Oliveira A, Sholl L, Fletcher C . Distinctive Nested Glomoid Neoplasm: Clinicopathologic Analysis of 20 Cases of a Mesenchymal Neoplasm With Frequent GLI1 Alterations and Indolent Behavior. Am J Surg Pathol. 2022; 47(1):12-24. DOI: 10.1097/PAS.0000000000001979. View

14.

Sioletic S, Dal Cin P, Fletcher C, Hornick J . Well-differentiated and dedifferentiated liposarcomas with prominent myxoid stroma: analysis of 56 cases. Histopathology. 2012; 62(2):287-93. DOI: 10.1111/j.1365-2559.2012.04348.x. View

15.

Pettus J, Kerr D, Stan R, Tse J, Sverrisson E, Bridge J . Primary myxoid and epithelioid mesenchymal tumor of the kidney with a novel GLI1-FOXO4 fusion. Genes Chromosomes Cancer. 2020; 60(2):116-122. DOI: 10.1002/gcc.22916. View

16.

Palsgrove D, Rooper L, Stevens T, Shin C, Damm D, Gagan J . GLI1-Altered Soft Tissue Tumors of the Head and Neck: Frequent Oropharyngeal Involvement, p16 Immunoreactivity, and Detectable Alterations by DDIT3 Break Apart FISH. Head Neck Pathol. 2022; 16(4):1146-1156. PMC: 9729462. DOI: 10.1007/s12105-022-01476-z. View

17.

Roberts W, Douglass E, Peiper S, Houghton P, Look A . Amplification of the gli gene in childhood sarcomas. Cancer Res. 1989; 49(19):5407-13. View

18.

Stein U, Eder C, Karsten U, Haensch W, Walther W, Schlag P . GLI gene expression in bone and soft tissue sarcomas of adult patients correlates with tumor grade. Cancer Res. 1999; 59(8):1890-5. View

19.

Nitta Y, Takeda M, Fujii T, Itami H, Tsukamoto S, Honoki K . A case of pericytic neoplasm in the shoulder with a novel DERA-GLI1 gene fusion. Histopathology. 2020; 78(3):466-469. DOI: 10.1111/his.14280. View

20.

Graham R, Nair A, Davila J, Jin L, Jen J, Sukov W . Gastroblastoma harbors a recurrent somatic MALAT1-GLI1 fusion gene. Mod Pathol. 2017; 30(10):1443-1452. DOI: 10.1038/modpathol.2017.68. View